Kyverna Therapeutics Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Kyverna Therapeutics, Inc. filed its Q1 2024 10-Q, detailing various licensing agreements and financial reporting.</b>

AI Summary

Kyverna Therapeutics, Inc. (KYTX) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Kyverna Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2024. The filing references various agreements including license and collaboration agreements with Intellia Therapeutics, Inc. and Kite Pharma, Inc. It also mentions agreements with National Institutes of Health and Gilead Sciences, Inc. The company's fiscal year ends on December 31. The filing details fair value measurements and stock compensation plans.

Why It Matters

For investors and stakeholders tracking Kyverna Therapeutics, Inc., this filing contains several important signals. The 10-Q filing provides an update on the company's financial status and ongoing business relationships, including significant collaborations. This filing is crucial for investors to assess the company's operational progress, financial health, and potential future developments based on its contractual obligations and asset valuations.

Risk Assessment

Risk Level: medium — Kyverna Therapeutics, Inc. shows moderate risk based on this filing. The company is in the biotechnology sector, which is inherently risky due to long development cycles, high R&D costs, and regulatory hurdles. Specific details on financial performance and cash burn are not yet available in this summary.

Analyst Insight

Investors should review the full 10-Q to understand the financial implications of the mentioned license agreements and the company's overall cash position and burn rate.

Key Numbers

• 2024-03-31 — Reporting Period End Date (10-Q filing)
• 2024-05-14 — Filing Date (10-Q filing)
• 2024-03-31 — Fair Value Measurements Date (10-Q filing)
• 2023-12-31 — Fair Value Measurements Date (10-Q filing)

Key Players & Entities

• Kyverna Therapeutics, Inc. (company) — Filer
• Intellia Therapeutics, Inc. (company) — Mentioned in license and collaboration agreements
• Kite Pharma, Inc. (company) — Mentioned in license and collaboration agreements
• Gilead Sciences, Inc. (company) — Mentioned in relation to agreements
• National Institutes of Health (company) — Mentioned in relation to patent license agreements

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: Biotechnology companies face significant regulatory hurdles in drug development and approval processes.
• Financial Viability [high — financial]: The company's ability to fund its research and development activities and achieve profitability is subject to market conditions and successful product development.
• Research and Development Risks [high — operational]: The success of Kyverna's therapeutic candidates is uncertain and dependent on complex scientific and clinical processes.
• Market Acceptance [medium — market]: The market acceptance and commercial success of any approved therapies are not guaranteed.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC). (Provides a comprehensive overview of a company's financial performance during a specific quarter.)

Fair Value Measurements

The price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. (Indicates how the company values its assets and liabilities, impacting its balance sheet.)

License and Collaboration Agreement

A contract granting rights to use intellectual property or to work jointly on a project, often involving payments and royalties. (Highlights key partnerships and potential revenue streams or cost-sharing arrangements.)

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share KYTX The Nasdaq Stock Mar

Filing Documents

• kytx-20240331.htm (10-Q) — 1967KB
• kytx-ex31_1.htm (EX-31.1) — 15KB
• kytx-ex31_2.htm (EX-31.2) — 15KB
• kytx-ex32_1.htm (EX-32.1) — 10KB
• kytx-ex32_2.htm (EX-32.2) — 10KB
• 0000950170-24-059628.txt (&nbsp;) — 7262KB
• kytx-20240331.xsd (EX-101.SCH) — 983KB
• kytx-20240331_htm.xml (XML) — 1056KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Balance Sheets 1 Condensed Statements of Operations and Comprehensive Loss 2 Condensed Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) 3 Condensed Statements of Cash Flows 4 Notes to Condensed Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II. OTHER INFORMATION 33 Item 1.

Legal Proceedings

Legal Proceedings 33 Item 1A.

Risk Factors

Risk Factors 33 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 88 Item 3. Defaults Upon Senior Securities 88 Item 4. Mine Safety Disclosures 88 Item 5. Other Information 89 Item 6. Exhibits 89

—FIN ANCIAL INFORMATION

PART I—FIN ANCIAL INFORMATION Ite m 1. Financial Statements (unaudited) Kyverna Therapeutics, Inc. Con densed Balance Sheets (in thousands, except share and per share data) (unaudited) March 31, December 31, 2024 2023 Assets Current assets Cash and cash equivalents $ 224,287 $ 34,647 Available-for-sale marketable securities 145,507 22,896 Prepaid expenses and other current assets 5,694 3,121 Total current assets 375,488 60,664 Restricted cash 570 565 Property and equipment, net 2,714 2,326 Operating lease right-of-use assets 8,486 6,494 Finance lease right-of-use assets 1,552 1,790 Other non-current assets 1,174 3,356 Total assets $ 389,984 $ 75,195 Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Current liabilities Accounts payable $ 7,451 $ 4,358 Accrued compensation 1,363 2,812 Accrued license expense – related party 6,250 6,250 Other accrued expenses and current liabilities 3,083 3,519 Operating lease liabilities, short-term portion 2,739 1,964 Finance lease liabilities, short-term portion 979 956 Total current liabilities 21,865 19,859 Operating lease liabilities, net of short-term portion 6,461 5,238 Finance lease liabilities, net of short-term portion 667 921 Total liabilities 28,993 26,018 Commitments and contingencies (Note 7) Redeemable convertible preferred stock, no par value no shares authorized, issued and outstanding as of March 31, 2024 $ 0.00001 par value, 114,556,997 shares authorized as of December 31, 2023; 114,556,997 shares issued and outstanding as of December 31, 2023; liquidation preference of $ 181,250 as of December 31, 2023 — 180,574 Stockholders' equity (deficit) Preferred stock, 10,000,000 shares authorized, $ 0.00001 par value, no shares issued and outstanding as of March 31, 2024 no shares authorized, issued, and outstanding as o

View Full Filing

View this 10-Q filing on SEC EDGAR